ZA87793B - Formulations suitable for the stabilisation of alpha-interferon - Google Patents

Formulations suitable for the stabilisation of alpha-interferon

Info

Publication number
ZA87793B
ZA87793B ZA87793A ZA87793A ZA87793B ZA 87793 B ZA87793 B ZA 87793B ZA 87793 A ZA87793 A ZA 87793A ZA 87793 A ZA87793 A ZA 87793A ZA 87793 B ZA87793 B ZA 87793B
Authority
ZA
South Africa
Prior art keywords
active ingredient
alpha
stabilisation
interferon
formulations suitable
Prior art date
Application number
ZA87793A
Other languages
English (en)
Inventor
Helmut Franz
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of ZA87793B publication Critical patent/ZA87793B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA87793A 1986-02-05 1987-02-04 Formulations suitable for the stabilisation of alpha-interferon ZA87793B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863603444 DE3603444A1 (de) 1986-02-05 1986-02-05 Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha

Publications (1)

Publication Number Publication Date
ZA87793B true ZA87793B (en) 1988-10-26

Family

ID=6293372

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA87793A ZA87793B (en) 1986-02-05 1987-02-04 Formulations suitable for the stabilisation of alpha-interferon

Country Status (20)

Country Link
EP (1) EP0231816B1 (ko)
JP (1) JPS62209024A (ko)
KR (1) KR870007698A (ko)
AT (1) ATE63823T1 (ko)
AU (1) AU601712B2 (ko)
CA (1) CA1295242C (ko)
DD (1) DD284602A5 (ko)
DE (2) DE3603444A1 (ko)
DK (1) DK164202C (ko)
ES (1) ES2028796T3 (ko)
FI (1) FI86144C (ko)
GR (1) GR3002270T3 (ko)
HU (1) HU196560B (ko)
IE (1) IE59697B1 (ko)
IL (1) IL81472A0 (ko)
NO (1) NO169638C (ko)
NZ (1) NZ219169A (ko)
PH (1) PH24377A (ko)
PT (1) PT84243B (ko)
ZA (1) ZA87793B (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5275804A (en) * 1986-02-25 1994-01-04 E. B. Michaels Research Associates, Inc. Process and composition for oral hygiene
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
DE3803312A1 (de) * 1988-02-04 1989-08-10 Gerd Prof Dr Med Gross Verwendung eines interferonenthaltenden gels
NO179479C (no) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
DE68917883T2 (de) * 1988-05-06 1995-02-23 Toray Industries Stabile interferon-beta-zusammensetzung.
US5244652A (en) * 1991-03-22 1993-09-14 E. B. Michaels Research Associates, Inc. Viscous surface active composition
US5389676A (en) * 1991-03-22 1995-02-14 E. B. Michaels Research Associates, Inc. Viscous surfactant emulsion compositions
EP0607275A4 (en) * 1991-10-11 1995-02-22 Mark Cedric Gillies TREATMENT OF OPHTHALMIC FIBROSE WITH ALPHA INTERFERON.
US5863530A (en) * 1991-10-11 1999-01-26 Spruson & Ferguson Treating ophthalmic fibrosis using interferon-α
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
FI106465B (fi) * 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv Menetelmä virusturvallisten farmaseuttisten koostumusten valmistamiseksi
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
ES2357474T3 (es) * 2000-03-07 2011-04-26 Rush-Presbyterian-St.Luke's Medical Center Composiciones y su uso para atrapar e inactivar microbios patógenos y espermatoziodes.
US6328987B1 (en) * 2000-11-03 2001-12-11 Jan Marini Skin Research, Inc. Cosmetic skin care compositions containing alpha interferon
CN1582167A (zh) * 2001-11-02 2005-02-16 积水化学工业株式会社 细胞因子诱导材料和细胞因子诱导装置
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
SG176254A1 (en) * 2009-05-29 2011-12-29 Filligent Ltd Composition for use in decreasing the transmission of human pathogens
WO2013131040A1 (en) 2012-03-01 2013-09-06 Firststring Research, Inc. Topical gels containing alpha connexin c-terminal (act) peptides
JP6081156B2 (ja) * 2012-11-15 2017-02-15 アルケア株式会社 ハイドロゲル
DE102012222365A1 (de) 2012-12-05 2014-06-05 Aesculap Ag Zusammensetzung zur Anwendung bei der Prophylaxe von post-chirurgischen Adhäsionen
CN105530950A (zh) * 2013-06-09 2016-04-27 艾弗兰纳特有限公司 包含Gc-巨噬细胞活化因子的组合物及其用途
GB2573933B (en) 2017-01-31 2022-07-13 Kimberly Clark Co Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
JPS6061535A (ja) * 1983-08-24 1985-04-09 エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト 製薬学的組成物
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
DE3484951D1 (de) * 1983-10-14 1991-09-26 Sumitomo Pharma Verlaengerte praeparate mit verzoegerter abgabe.
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
JPS60228422A (ja) * 1984-04-26 1985-11-13 Suntory Ltd 安定化された生理活性物質製剤
JPS60260523A (ja) * 1984-06-07 1985-12-23 Asahi Chem Ind Co Ltd インタ−フエロンの凍結乾燥医薬組成物

Also Published As

Publication number Publication date
PT84243A (de) 1987-03-01
PT84243B (pt) 1989-09-14
NZ219169A (en) 1990-04-26
DK164202B (da) 1992-05-25
DK58387A (da) 1987-08-06
FI870457A (fi) 1987-08-06
CA1295242C (en) 1992-02-04
EP0231816A3 (en) 1987-09-23
KR870007698A (ko) 1987-09-21
ES2028796T3 (es) 1992-07-16
NO169638B (no) 1992-04-13
IE870295L (en) 1987-08-05
ATE63823T1 (de) 1991-06-15
IE59697B1 (en) 1994-03-23
EP0231816B1 (de) 1991-05-29
DK164202C (da) 1992-10-19
IL81472A0 (en) 1987-09-16
HU196560B (en) 1988-12-28
EP0231816A2 (de) 1987-08-12
NO870441L (no) 1987-08-06
DE3603444A1 (de) 1987-08-06
AU6829287A (en) 1987-08-06
PH24377A (en) 1990-06-13
HUT43494A (en) 1987-11-30
DE3770280D1 (de) 1991-07-04
FI86144C (fi) 1992-07-27
DD284602A5 (de) 1990-11-21
FI86144B (fi) 1992-04-15
NO169638C (no) 1992-07-22
JPS62209024A (ja) 1987-09-14
DK58387D0 (da) 1987-02-04
AU601712B2 (en) 1990-09-20
NO870441D0 (no) 1987-02-04
FI870457A0 (fi) 1987-02-03
GR3002270T3 (en) 1992-12-30

Similar Documents

Publication Publication Date Title
ZA87793B (en) Formulations suitable for the stabilisation of alpha-interferon
HK1040631A1 (en) Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues.
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
CA2058428A1 (en) Analgesic formulations
ES2009216A6 (es) Metodo de preparar un derivado de interleucina-lalfa.
AU7076887A (en) Nasal administration of drugs
ZA928170B (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-D-neuraminic acid
DK0395329T3 (da) Sammensætning i form af et skum indeholdende 5-aminosalicylsyre til intrarektal administration
IL108071A0 (en) Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines their preparation and pharmaceutical compositions containing them
IL68456A0 (en) Pharmaceutical compositions comprising perfluorohydrocarbons as vehicles
IL79816A0 (en) Pharmaceutical composition comprising a drug-polymer matrix
ZA881053B (en) Prostaglandin e1 derivatives as pharmacologically active agents,and pharmaceutical compositions containing these compounds,especially for transcutaneous administration
DK305087A (da) Buprenorphinholdigt farmaceutisk suppositorium
GB2021409A (en) Pharmaceutical composition
AU581855B2 (en) 1-(4'-alkylsulphonylphenyl)-2-amino-1, 3-propanediol n-substituted derivatives
IE56229B1 (en) 2-piperazinyl-or-homopiperazinyl-quinazoline derivatives their production and pharmaceutical compositions containing them
AU581856B2 (en) 1-(4'-alkylthiophenyl)-2-amino-1, 3-propanediol N-substituted derivatives
IL106289A0 (en) Phospholipid derivatives, their preparation and pharmaceutical compositions containing them
MY104088A (en) Peptide-drugs compositions containing (alpha)-aminoboroic acid derivatives.
EP0355899A3 (en) Nucleotide derivatives
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
ES2135424T3 (es) Composicion oral a base de ibuprofeno.
IT8723007A0 (it) Composizioni farmaceutiche per uso orale ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo, e procedimento per prepararle